Influenza, also called as flu or grippe is an acute viral infection of respiratory tract. The disease can be remarked by symptoms such as fevers, chills, and weakness coupled with soreness in head and abdomen. Influenza flu has prevention as well as treatments. Prevention includes vaccines for protection against influenza virus for upcoming seasons. Based on effectiveness of the vaccine against number of flu virus, the vaccines are classified as trivalent vaccine (three flu virus) or quadrivalent (four flu virus). Vaccine can be administered intramuscular, intranasal or intradermal. Increasing pipelines products, rising disease prevalence, and new entrant aiming to manufacture influenza vaccine by novel technology such as cell-based or recombinant based are the key factors driving growth of the influenza vaccine market.
Grab Sample of this Report at: @
Market Dynamics
The significant growth of influenza vaccine market is expected to be attributed by rich pipeline product with novel approach by the major market players as well as the emerging market players. For instance, Mymetrics Corporation is evaluating influenza vaccine via intra nasal form of dosage to inhibit the virus at mucosal level by developing mucosal as well as blood antibodies. Moreover, companies are planning strategically to reduce the burden of vaccine development via partnering with other manufacturers. For instance, the influenza vaccine of Mymetics is been developed with Abbott Biologicals under the contract of out-licensing. Moreover, the governmental organization are continuously aiming to propel the study of universal influenza vaccine to reduce the epidemiology to influenza virus during the seasonal outbreaks. For instance, in 2018, the Human Vaccines Project, a nonprofit consortium of academic, government and industry medical researchers, is engaged in launching Universal Influenza Vaccine Initiative to accelerate the development of universal influenza vaccine.
Key features of the study:
• This report provides in-depth analysis of the influenza vaccine market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global influenza vaccine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Seqirus Vaccines Limited, GlaxoSmithKline plc, ID Biomedical Corporation, Sanofi, Protein Sciences Corp., and MedImmmune LLC
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics.
• The global influenza vaccine market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of influenza vaccine, research and consulting firms, new entrants, and financial analysts
• Various strategy matrices used in analyzing the influenza vaccine market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
• Global Influenza Vaccine Market, By Vaccine Type:
o Trivalent Vaccines
o Quadrivalent Vaccines
• Global Influenza Vaccine Market, By Virus Type:
o Influenza Virus A
o Influenza Virus B
• Global Influenza Vaccine Market, By Age Group:
o Pediatrics
o Adults
• Global Influenza Vaccine Market, By Region:
o North America
o By Vaccine Type:
o Trivalent Vaccines
o Quadrivalent Vaccines
o By Virus Type:
o Influenza Virus A
o Influenza Virus B
o By Age Group:
o Pediatrics
o Adults
o By Country:
o U.S.
o Canada
o Latin America
o By Vaccine Type:
o Trivalent Vaccines
o Quadrivalent Vaccines
o By Virus Type:
o Influenza Virus A
o Influenza Virus B
o By Age Group:
o Pediatrics
o Adults
o By Country:
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
o By Vaccine Type:
o Trivalent Vaccines
o Quadrivalent Vaccines
o By Virus Type:
o Influenza Virus A
o Influenza Virus B
o By Age Group:
o Pediatrics
o Adults
o By Country:
o Germany
o U.K.
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o By Vaccine Type:
o Trivalent Vaccines
o Quadrivalent Vaccines
o By Virus Type:
o Influenza Virus A
o Influenza Virus B
o By Age Group:
o Pediatrics
o Adults
o By Country:
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
o By Vaccine Type:
o Trivalent Vaccines
o Quadrivalent Vaccines
o By Virus Type:
o Influenza Virus A
o Influenza Virus B
o By Age Group:
o Pediatrics
o Adults
o By Country:
o GCC
o Israel
o Rest of Middle East
o Africa
o By Vaccine Type:
o Trivalent Vaccines
o Quadrivalent Vaccines
o By Virus Type:
o Influenza Virus A
o Influenza Virus B
o By Age Group:
o Pediatrics
o Adults
o By Country:
o North Africa
o Central Africa
o South Africa
• Company Profiles
o Seqirus Vaccines Limited*
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategies
o GlaxoSmithKline plc
o Sanofi
o MedImmmune LLC
Get Exclusive Discount at: @
Strategies “*” marked represents similar segmentation in other categories in the respective section.
Industry Forecast Research 